BridgeBio and US FDA agreed on a path to accelerated approval for BB-418, a Phase III oral candidate for a subset of limb-girdle MD patients. If successful, it would bring BridgeBio’s third product to market.

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.

The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.

An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.